{"id":226,"date":"2013-11-18T14:20:44","date_gmt":"2013-11-18T19:20:44","guid":{"rendered":"http:\/\/www.gqr-lmc-nmp.ca\/system\/?p=226"},"modified":"2014-05-06T14:21:32","modified_gmt":"2014-05-06T18:21:32","slug":"sanofi-suspend-le-developpement-clinique-de-lagent-experimental-jak2-fedratinib-sar302503","status":"publish","type":"post","link":"https:\/\/www.gqr-lmc-nmp.ca\/system\/2013\/11\/18\/sanofi-suspend-le-developpement-clinique-de-lagent-experimental-jak2-fedratinib-sar302503\/","title":{"rendered":"Sanofi suspend le d\u00e9veloppement clinique de l\u2019agent exp\u00e9rimental JAK2, fedratinib (SAR302503)"},"content":{"rendered":"<div dir=\"ltr\" style=\"font-size: 14.72px; font-family: sans-serif; left: 71.84px; top: 365.347px; transform: rotate(0deg) scale(0.964198, 1); transform-origin: 0% 0% 0px;\" data-angle=\"0\" data-font-name=\"g_font_19_0\" data-canvas-width=\"372.18049109184255\">Sanofi (EURONEXT: SAN et NYSE: SNY) annonce aujourd\u2019hui avoir pris la d\u00e9cision d\u2019interrompre tous les essais cliniques de son agent exp\u00e9rimental fedratinib (SAR302503), un inhibiteur JAK2, et d\u2019annuler ses projets de demande d\u2019homologation aupr\u00e8s des agences r\u00e9glementaires.<\/div>\n<div dir=\"ltr\" style=\"font-size: 14.72px; font-family: sans-serif; left: 71.84px; top: 365.347px; transform: rotate(0deg) scale(0.964198, 1); transform-origin: 0% 0% 0px;\" data-angle=\"0\" data-font-name=\"g_font_19_0\" data-canvas-width=\"372.18049109184255\">&nbsp;<\/div>\n<div dir=\"ltr\" style=\"font-size: 14.72px; font-family: sans-serif; left: 503.293px; top: 416.067px; transform: rotate(0deg) scale(1.0167, 1); transform-origin: 0% 0% 0px;\" data-angle=\"0\" data-font-name=\"g_font_19_0\" data-canvas-width=\"205.37344612060542\">A la suite d\u2019une analyse approfondie du profil b\u00e9n\u00e9fices-risques et de consultations avec la Food and Drug Administration (FDA) des Etats-Unis, les investigateurs des \u00e9tudes cliniques et des experts ind\u00e9pendants en neurologie et neuroradiologie, Sanofi a estim\u00e9 que les risques que le fedratinib faisait peser sur les patients \u00e9taient sup\u00e9rieurs aux b\u00e9n\u00e9fices qu\u2019il pourrait leur apporter.<\/div>\n<div dir=\"ltr\" style=\"font-size: 14.72px; font-family: sans-serif; left: 71.84px; top: 449.667px; transform: rotate(0deg) scale(1.00738, 1); transform-origin: 0% 0% 0px;\" data-angle=\"0\" data-font-name=\"g_font_19_0\" data-canvas-width=\"582.2643373528288\">&nbsp;<\/div>\n<div dir=\"ltr\" style=\"font-size: 14.72px; font-family: sans-serif; left: 71.84px; top: 534.013px; transform: rotate(0deg) scale(1.00678, 1); transform-origin: 0% 0% 0px;\" data-angle=\"0\" data-font-name=\"Helvetica\" data-canvas-width=\"43.29152129018784\">Cette d\u00e9cision est cons\u00e9cutive au signalement r\u00e9cent de cas d\u2019enc\u00e9phalopathie de Gayet-Wernicke chez des patients inclus dans des essais cliniques du fedratinib. La FDA a somm\u00e9 Sanofi de suspendre tous les essais cliniques en attendant que le Groupe ait men\u00e9 toutes les investigations n\u00e9cessaires pour garantir la s\u00e9curit\u00e9 d\u2019emploi du fedratinib pour les patients. Sanofi a imm\u00e9diatement demand\u00e9 aux investigateurs de mettre un terme au traitement par fedratinib chez les patients inclus dans les essais cliniques.<\/div>\n<div dir=\"ltr\" style=\"font-size: 14.72px; font-family: sans-serif; left: 71.84px; top: 534.013px; transform: rotate(0deg) scale(1.00678, 1); transform-origin: 0% 0% 0px;\" data-angle=\"0\" data-font-name=\"Helvetica\" data-canvas-width=\"43.29152129018784\">&nbsp;<\/div>\n<div dir=\"ltr\" style=\"font-size: 14.72px; font-family: sans-serif; left: 71.84px; top: 534.013px; transform: rotate(0deg) scale(1.00678, 1); transform-origin: 0% 0% 0px;\" data-angle=\"0\" data-font-name=\"Helvetica\" data-canvas-width=\"43.29152129018784\">Pour plus d&rsquo;information veuillez lire le <a href=\"http:\/\/www.sanofi.com\/Images\/34935_20131118_JAK-2-FEDRATINIB_fr.pdf\" target=\"_blank\">communiqu\u00e9 de presse<\/a>.<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi (EURONEXT: SAN et NYSE: SNY) annonce aujourd\u2019hui avoir pris la d\u00e9cision d\u2019interrompre tous les essais cliniques de son agent\u2026<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/posts\/226"}],"collection":[{"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/comments?post=226"}],"version-history":[{"count":2,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/posts\/226\/revisions"}],"predecessor-version":[{"id":228,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/posts\/226\/revisions\/228"}],"wp:attachment":[{"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/media?parent=226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/categories?post=226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/tags?post=226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}